TB Alternative Assets Ltd. Lowers Position in Alnylam Pharmaceuticals, Inc. $ALNY

Key Points

• TB Alternative Assets Ltd. has significantly reduced its stake in Alnylam Pharmaceuticals by 86.3%, selling 7,909 shares and bringing its holdings down to just 1,259 shares, valued at approximately $411,000.
• Recent insider trading activity includes Director Colleen F. Reitan selling 18,000 shares for about $8.4 million, leading to a 95.87% decrease in their ownership.
• Multiple analysts have upgraded their target prices for Alnylam Pharmaceuticals, with some raising it to as high as $570.00, reflecting a strong bullish sentiment among research firms.

TB Alternative Assets Ltd. trimmed its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 86.3% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,259 shares of the biopharmaceutical company's stock after selling 7,909 shares during the quarter. TB Alternative Assets Ltd.'s holdings in Alnylam Pharmaceuticals were worth $411,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Bessemer Group Inc. boosted its stake in shares of Alnylam Pharmaceuticals by 176.9% during the 1st quarter. Bessemer Group Inc. now owns 108 shares of the biopharmaceutical company's stock worth $29,000 after acquiring an additional 69 shares in the last quarter. Crossmark Global Holdings Inc. acquired a new position in Alnylam Pharmaceuticals in the 1st quarter worth about $275,000. Strs Ohio purchased a new position in Alnylam Pharmaceuticals during the first quarter worth approximately $7,781,000. GAMMA Investing LLC grew its holdings in Alnylam Pharmaceuticals by 14.3% in the first quarter. GAMMA Investing LLC now owns 616 shares of the biopharmaceutical company's stock valued at $166,000 after purchasing an additional 77 shares during the period. Finally, Brighton Jones LLC purchased a new stake in shares of Alnylam Pharmaceuticals in the fourth quarter valued at approximately $243,000. Institutional investors and hedge funds own 92.97% of the company's stock.

Insider Transactions at Alnylam Pharmaceuticals

In other news, Director Colleen F. Reitan sold 18,000 shares of the stock in a transaction that occurred on Tuesday, September 9th. The shares were sold at an average price of $467.60, for a total value of $8,416,800.00. Following the completion of the transaction, the director directly owned 775 shares in the company, valued at $362,390. This trade represents a 95.87% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Michael W. Bonney sold 11,250 shares of the business's stock in a transaction that occurred on Monday, August 18th. The stock was sold at an average price of $450.00, for a total value of $5,062,500.00. Following the sale, the director directly owned 16,804 shares in the company, valued at approximately $7,561,800. The trade was a 40.10% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 75,594 shares of company stock worth $33,968,256 over the last ninety days. Insiders own 1.50% of the company's stock.

Analyst Ratings Changes

A number of research analysts have recently issued reports on the company. BMO Capital Markets increased their target price on Alnylam Pharmaceuticals from $450.00 to $470.00 and gave the company an "outperform" rating in a research report on Friday, September 5th. Royal Bank Of Canada lifted their target price on shares of Alnylam Pharmaceuticals from $435.00 to $500.00 and gave the company an "outperform" rating in a research report on Friday, September 19th. UBS Group boosted their target price on shares of Alnylam Pharmaceuticals from $403.00 to $550.00 and gave the stock a "buy" rating in a research note on Friday, August 1st. Evercore ISI raised their price target on shares of Alnylam Pharmaceuticals from $280.00 to $515.05 and gave the company an "outperform" rating in a research note on Thursday, September 11th. Finally, HC Wainwright reiterated a "buy" rating and set a $570.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Tuesday, September 2nd. Twenty-four research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat.com, Alnylam Pharmaceuticals presently has an average rating of "Moderate Buy" and a consensus price target of $439.58.

Alnylam Pharmaceuticals Stock Performance

Shares of NASDAQ ALNY opened at $458.37 on Thursday. Alnylam Pharmaceuticals, Inc. has a 12-month low of $205.87 and a 12-month high of $484.21. The company has a market cap of $60.08 billion, a PE ratio of -185.57 and a beta of 0.32. The stock has a 50 day simple moving average of $423.49 and a 200-day simple moving average of $328.53. The company has a current ratio of 2.80, a quick ratio of 2.75 and a debt-to-equity ratio of 4.10.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last announced its earnings results on Thursday, July 31st. The biopharmaceutical company reported $0.32 earnings per share for the quarter, beating the consensus estimate of ($0.54) by $0.86. Alnylam Pharmaceuticals had a negative return on equity of 273.52% and a negative net margin of 12.96%.The firm had revenue of $773.69 million for the quarter, compared to the consensus estimate of $633.54 million. During the same quarter in the previous year, the business earned ($0.13) EPS. The firm's revenue for the quarter was up 17.3% on a year-over-year basis. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. On average, equities research analysts forecast that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.